Find trials
Search tips

Collection of Mayo SDH Mutant Paraganglioma Tumor Tissue for Establishment of Cultured Tumor Cell Lines

Overview

About this study

The purpose of this study is to to develop cultured human tumor cell lines from paraganglioma/ pheochromocytoma (PGL) tumors. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients (heterozygous for germline SDH mutations (subunits B, C or D) undergoing surgery for confirmed primary or metastatic PGL of abdomen, pelvis, mediastinum, neck or head. 
  • Tumor size should be consistent for greater than 1 cc viable tumor tissue after retention of clinical pathology specimen.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Louis Maher, Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Louis Maher Ph.D.

(507) 538-1123

maher@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

John Copland, Ph.D.

Closed for enrollment

Contact information:

John Copland Ph.D.

(904) 953-6120

Copland.John@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20396721

Mayo Clinic Footer